Cargando…

Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Guoyi, Li, Sha, Zhang, Cheng, Chen, Haiyong, Wang, Ning, Feng, Yibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463270/
https://www.ncbi.nlm.nih.gov/pubmed/34589395
http://dx.doi.org/10.1016/j.apsb.2020.12.020
_version_ 1784572366025654272
author Tang, Guoyi
Li, Sha
Zhang, Cheng
Chen, Haiyong
Wang, Ning
Feng, Yibin
author_facet Tang, Guoyi
Li, Sha
Zhang, Cheng
Chen, Haiyong
Wang, Ning
Feng, Yibin
author_sort Tang, Guoyi
collection PubMed
description Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
format Online
Article
Text
id pubmed-8463270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84632702021-09-28 Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management Tang, Guoyi Li, Sha Zhang, Cheng Chen, Haiyong Wang, Ning Feng, Yibin Acta Pharm Sin B Review Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN. Elsevier 2021-09 2021-02-02 /pmc/articles/PMC8463270/ /pubmed/34589395 http://dx.doi.org/10.1016/j.apsb.2020.12.020 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Tang, Guoyi
Li, Sha
Zhang, Cheng
Chen, Haiyong
Wang, Ning
Feng, Yibin
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title_full Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title_fullStr Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title_full_unstemmed Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title_short Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
title_sort clinical efficacies, underlying mechanisms and molecular targets of chinese medicines for diabetic nephropathy treatment and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463270/
https://www.ncbi.nlm.nih.gov/pubmed/34589395
http://dx.doi.org/10.1016/j.apsb.2020.12.020
work_keys_str_mv AT tangguoyi clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement
AT lisha clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement
AT zhangcheng clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement
AT chenhaiyong clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement
AT wangning clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement
AT fengyibin clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement